Company intelligence / Profile preview
Phoenicis Therapeutics
Foxboro, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Phoenicis Therapeutics focused on developing rare dermatological therapies using recombinant proteins. Its lead preclinical asset targeted cicatrix via decorin agonism. A previous program targeting COL7A1 for epidermolysis bullosa dystrophica was discontinued. There are no reported clinical results or approvals to date[1][3].
- Therapeutic areas
- Dermatology
- Modalities
- Recombinant protein
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
ProQR Therapeutics N.V. held a minority interest (~4%) following the Wings acquisition but no major ongoing partnerships are listed post-acquisition[5].
Beyond the preview
Go deeper on Phoenicis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phoenicis Therapeutics.